Cargando…
An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors
PURPOSE: To determine ombrabulin’s maximum tolerated dose and dose recommended for Japanese patients with advanced solid tumors and to assess its antitumor activity and overall safety and pharmacokinetic profiles. METHODS: This was a multi-center, open-label, sequential-cohort, dose-escalation phase...
Autores principales: | Murakami, H., Kurata, T., Onozawa, Y., Watanabe, J., Ono, A., Takahashi, T., Yamamoto, N., Fujisaka, Y., Kiyota, H., Hayashi, H., Tanaka, K., Nakagawa, K., Kuroda, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931931/ https://www.ncbi.nlm.nih.gov/pubmed/24477603 http://dx.doi.org/10.1007/s00280-014-2388-x |
Ejemplares similares
-
A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer
por: Sakiyama, T, et al.
Publicado: (2015) -
Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks
por: Kerbusch, T, et al.
Publicado: (2004) -
A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours
por: Eskens, F A L M, et al.
Publicado: (2014) -
XG-102 administered to healthy male volunteers as a single intravenous infusion: a randomized, double-blind, placebo-controlled, dose-escalating study
por: Deloche, Catherine, et al.
Publicado: (2014) -
Model-Informed Development of Sotalol Loading and Dose Escalation Employing an Intravenous Infusion
por: Somberg, John C., et al.
Publicado: (2020)